GLP-1 Receptor Agonists Similarly Effective Across Age, Race, Starting Weight

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Judith Stewart, BPharm. Last updated on March 11, 2026.

via HealthDay

WEDNESDAY, March 11, 2026 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review published online March 2 in JAMA Internal Medicine.

G. Caleb Alexander, M.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues conducted a systematic literature review to examine the heterogeneity of treatment effects from GLP-1 RAs on weight loss by age, sex, race and ethnicity, baseline body mass index (BMI), and baseline hemoglobin A1c (HbA1c).

Based on 41 articles representing 64 randomized controlled trials (RCTs), the researchers found that 21 evaluated semaglutide (43.8 percent) and nine evaluated dulaglutide (18.8 percent). Heterogeneity of treatment effects was most commonly evaluated using baseline BMI (36 RCTs), HbA1c (24 RCTs), and age (21 RCTs), and was less commonly evaluated by ethnicity (12 RCTs), race (11 RCTs), and sex (10 RCTs). Using data from six trials (19,906 patients), weight loss was greater among women (10.9 percent) than men (6.8 percent). Age did not show significant heterogeneity of treatment effects (based on seven trials; 4,314 patients), nor did race (nine trials; 25,229 patients), ethnicity (seven trials; 8,328 patients), baseline BMI (15 trials; 9,473 patients across three analyses), or baseline HbA1c (four trials; 1,886 patients).

"The popularity and the cost of GLP-1 RAs are such that we need more studies like this to better understand the benefits of these products in clinical practice, especially for individuals that might be under-represented in clinical trials," Alexander said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-12 01:49

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords